No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ACLX241220P145000
- 0.00
- 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest145.00Strike Price0.00Turnover0.00%IV-91.95%PremiumDec 20, 2024Expiry Date69.46Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.09Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Buy Rating for Arcellx Inc. Based on Promising Efficacy and Safety of BCMA CAR-T Therapy in IMMagine-1 Study
Morgan Stanley Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $111
Truist Financial Initiates Arcellx(ACLX.US) With Buy Rating
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $111 to $122
Arcellx Inc (ACLX) Gets a Buy From Truist Financial
Promising Outlook for Arcellx Inc: Anito-cel Therapy Positioned as a Safer Alternative With Strong Market Potential